Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 35 条
  • [21] Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs
    Reidy-Lagunes, D.
    Kulke, M.
    Wolin, E.
    Mirakhur, B.
    Massien, C.
    Caplin, M.
    Baudin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 118 - 118
  • [22] Post-Hoc Analysis of CLARINET Phase III Study to Investigate the Influence of Diabetic Status on Progression-Free Survival (PFS) of Patients with Neuroendocrine Tumours (NETs) Treated with Lanreotide (LAN) or Placebo (PBO)
    Pusceddu, S.
    Prinzi, N.
    Torchio, M.
    Vernieri, C.
    Di Maio, M.
    Buzzoni, R.
    Mazzaferro, V
    Thanh, Truong X. M.
    De Braud, F.
    NEUROENDOCRINOLOGY, 2019, 108 : 159 - 159
  • [23] Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
    Diener, Hans Christoph
    McAllister, Peter
    Jurgens, Tim P.
    Kessler, Yoel
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Barash, Steve
    Silberstein, Stephen D.
    CEPHALALGIA, 2022, 42 (08) : 769 - 780
  • [24] Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials
    Choy, Ernest H. S.
    Mease, Philip J.
    Kajdasz, Daniel K.
    Wohlreich, Madelaine M.
    Crits-Christoph, Paul
    Walker, Daniel J.
    Chappell, Amy S.
    CLINICAL RHEUMATOLOGY, 2009, 28 (09) : 1035 - 1044
  • [25] Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials
    Ernest H. S. Choy
    Philip J. Mease
    Daniel K. Kajdasz
    Madelaine M. Wohlreich
    Paul Crits-Christoph
    Daniel J. Walker
    Amy S. Chappell
    Clinical Rheumatology, 2009, 28 : 1035 - 1044
  • [26] A prospective, multicenter, single-arm, open-label, phase 3 study of Lanreotide Autogel (LAN) in Chinese patients with unresectable, locally advanced or metastatic grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Lu, M.
    Li, E.
    Cao, D.
    Chen, J.
    Zhang, N.
    Hu, H.
    Zou, J. Y.
    Shi, X.
    Truong, Thanh X. M.
    Shen, L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 230 - 230
  • [27] Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials (vol 22, 16, 2021)
    Smith, Timothy R.
    Spierings, Egilius L. H.
    Cady, Roger
    Hirman, Joe
    Schaeffler, Barbara
    Shen, Vivienne
    Sperling, Bjorn
    Brevig, Thomas
    Josiassen, Mette Krog
    Brunner, Elizabeth
    Honeywell, Loan
    Mehta, Lahar
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [28] The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis
    Jacobson, Ira M.
    Bourgeois, Stefan
    Mathurin, Phillipe
    Thuluvath, Paul
    Ryder, Stephen D.
    Gerken, Guido
    Hernandez, Candido
    Vanstraelen, Kim
    Scherbakovsky, Stacey
    Osinusi, Anu
    Tedesco, Dana
    Foster, Graham R.
    JOURNAL OF VIRAL HEPATITIS, 2023, 30 (05) : 448 - 454
  • [29] Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
    Lehrke, Michael
    Marx, Nikolaus
    Patel, Sanjay
    Seck, Thomas
    Crowe, Susanne
    Cheng, Karen
    von Eynatten, Maximilian
    Johansen, Odd Erik
    CLINICAL THERAPEUTICS, 2014, 36 (08) : 1130 - 1146
  • [30] Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies
    Brodie, Martin J.
    Whitesides, John
    Schiemann, Jimmy
    D'Souza, Joseph
    Johnson, Martin E.
    EPILEPSY RESEARCH, 2016, 127 : 114 - 118
1234